A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2013-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect and safety of AZD6765 in patients with
major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a
channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.